Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
|
N Engl J Med
|
2012
|
52.99
|
2
|
Nivolumab plus ipilimumab in advanced melanoma.
|
N Engl J Med
|
2013
|
17.53
|
3
|
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
|
N Engl J Med
|
2015
|
14.71
|
4
|
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
|
J Clin Oncol
|
2014
|
9.86
|
5
|
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
|
Nat Genet
|
2012
|
7.00
|
6
|
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
|
Lancet Oncol
|
2012
|
5.32
|
7
|
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
|
Pigment Cell Melanoma Res
|
2010
|
4.50
|
8
|
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
|
J Clin Oncol
|
2002
|
4.15
|
9
|
A clinical development paradigm for cancer vaccines and related biologics.
|
J Immunother
|
2007
|
2.97
|
10
|
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
|
Proc Natl Acad Sci U S A
|
2011
|
2.90
|
11
|
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
|
J Transl Med
|
2010
|
2.65
|
12
|
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.
|
J Neurosurg
|
2012
|
2.28
|
13
|
Genome-wide screen of promoter methylation identifies novel markers in melanoma.
|
Genome Res
|
2009
|
2.13
|
14
|
Advances in the systemic treatment of metastatic melanoma.
|
Oncology (Williston Park)
|
2013
|
2.05
|
15
|
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
|
Semin Oncol
|
2010
|
2.00
|
16
|
MicroRNA signatures differentiate melanoma subtypes.
|
Cell Cycle
|
2011
|
1.99
|
17
|
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.
|
PLoS One
|
2009
|
1.80
|
18
|
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
|
Leuk Res
|
2007
|
1.57
|
19
|
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
|
Cancer Gene Ther
|
2003
|
1.40
|
20
|
A phase 2 trial of dasatinib in advanced melanoma.
|
Cancer
|
2010
|
1.40
|
21
|
Melanoma: a model for testing new agents in combination therapies.
|
J Transl Med
|
2010
|
1.39
|
22
|
Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.
|
Sci Transl Med
|
2014
|
1.30
|
23
|
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
|
Clin Cancer Res
|
2011
|
1.27
|
24
|
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
|
Clin Cancer Res
|
2003
|
1.24
|
25
|
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
|
Yale J Biol Med
|
2011
|
1.23
|
26
|
Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation.
|
Clin Cancer Res
|
2005
|
1.22
|
27
|
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.
|
J Transl Med
|
2007
|
1.21
|
28
|
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
|
J Clin Oncol
|
2004
|
1.16
|
29
|
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
|
Cancer Chemother Pharmacol
|
2004
|
1.14
|
30
|
Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer.
|
Clin Cancer Res
|
2005
|
1.13
|
31
|
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
|
Leuk Res
|
2003
|
1.13
|
32
|
Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
|
J Immunother
|
2008
|
1.13
|
33
|
Plasma markers for identifying patients with metastatic melanoma.
|
Clin Cancer Res
|
2011
|
1.12
|
34
|
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
|
Clin Cancer Res
|
2004
|
1.08
|
35
|
A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer.
|
PLoS One
|
2013
|
1.08
|
36
|
Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells.
|
Lab Invest
|
2008
|
1.07
|
37
|
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010".
|
J Transl Med
|
2011
|
1.02
|
38
|
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.
|
Clin Cancer Res
|
2006
|
1.01
|
39
|
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
|
Leuk Res
|
2006
|
1.00
|
40
|
Ipilimumab-induced perforating colitis.
|
J Clin Gastroenterol
|
2013
|
1.00
|
41
|
Biology of advanced uveal melanoma and next steps for clinical therapeutics.
|
Pigment Cell Melanoma Res
|
2014
|
0.99
|
42
|
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
|
Leuk Res
|
2007
|
0.97
|
43
|
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
|
Clin Cancer Res
|
2009
|
0.97
|
44
|
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
|
Clin Cancer Res
|
2005
|
0.90
|
45
|
Melanoma brain metastases: is it time to reassess the bias?
|
Curr Probl Cancer
|
2011
|
0.90
|
46
|
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
|
J Clin Oncol
|
2005
|
0.90
|
47
|
A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer.
|
Invest New Drugs
|
2005
|
0.90
|
48
|
Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?
|
Curr Opin Investig Drugs
|
2010
|
0.87
|
49
|
In vitro studies of dasatinib, its targets and predictors of sensitivity.
|
Pigment Cell Melanoma Res
|
2011
|
0.83
|
50
|
Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma.
|
J Clin Oncol
|
2011
|
0.81
|
51
|
Chitinase-like proteins in lung injury, repair, and metastasis.
|
Proc Am Thorac Soc
|
2012
|
0.81
|
52
|
Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation.
|
Cornea
|
2016
|
0.75
|
53
|
Relative roles of targeted therapies and immunotherapies in melanoma.
|
Oncology (Williston Park)
|
2012
|
0.75
|
54
|
Developing enabling technologies for the success of cancer immunotherapy.
|
Curr Opin Investig Drugs
|
2004
|
0.75
|